All news

Humana surges as CMS star ratings beat expectations

Alpha Vantage · StocksToTrade · · AI-summarised by FinFlash

Humana Inc. (HUM) shares surged over 12% after the release of 2027 CMS Medicare Advantage Star ratings came in better than investor expectations. Barclays and Cantor Fitzgerald both raised their price targets, citing improved Medicare Advantage margins and potential bonus payments. The company's focus on low-premium, benefit-rich plans and expansion of Chronic Condition Special Needs Plans is expected to support future growth. Analyst consensus stands at 13 Buy, 12 Hold and 1 Sell, with an average target of $423.74 versus $387.12.

Read original source

HUM company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.